Monte Rosa Therapeutics Inc. (Nasdaq: GLUE) Stock Rockets After License Agreement with Novartis

October 29, 2024

One stock that is highly likely to be on the radars of investors this morning is that of Monte Rosa Therapeutics Inc. (Nasdaq: GLUE), which delivered staggering gains of 94% on Monday. Let’s take a look at the development that led to such gains. Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Yesterday, the company garnered considerable attention from…

Read More >>